Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Research, projects and publications in this group We are a multidisciplinary group of statisticians, methodologists, clinical trial programme managers, trial managers and data scientists within the ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

Image: Person walking towards the beach. Credits: Pixabay. Most people are aware of the benefits of exercise – it has been associated with improvements in overall health for some time. It makes sense ...

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos Scientists have ...

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy ...

Whole-body MRI scans provide powerful insights into treatment effectiveness and long-term outcomes for patients with myeloma, an incurable but treatable blood cancer. Results from the iTIMM study led ...

Image: A scanning electron microscope image of a prostate cancer cell. Credit: Anne Weston, Francis Crick Institute. CC BY-NC 4.0. At The Institute of Cancer Research, London, we often refer to ...

Image: A small round melanoma cell at the top and a large, flat melanoma cell underneath it. Credit: Professor Chris Bakal, the ICR. Cancer cells can shrink or super-size themselves to survive drug ...

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...